Abstract: The present invention refers to oligonucleotides comprising 10 to 25 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with mRNA of angiotensin-converting enzyme 2 (ACE2) of SEQ ID NO.1 and/or with pre-mRNA of ACE2 of SEQ ID NO.2 resulting in a reduction of the level of ACE2, ACE2 mRNA, ACE2 pre-mRNA or a combination thereof of 30 to 99% compared to an untreated control. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide. The oligonucleotide and the pharmaceutical composition are used in a method of preventing and/or treating a viral disease.

Abstract: A device (10) for performing an allergy test comprising a container unit (11) having a first surface (12) and a second surface (13). The container unit (11) comprising a plurality of cavities (22) each arranged for receiving an allergen container (14) comprising a supporting material (18) and a pricking tool, which is secured at a location of the supporting material (18). The supporting material (18) is arranged, when a pressure force is applied on the second surface (13), for being compressed thereby causing the pricking tool (19) for being displaced from a first position (25), wherein at said first position the at least one pricking tip (24) is at a first distance from the first surface (12), to a second position (26), wherein at said second position (26) the at least one pricking tip (24) is at a second distance from the first surface (12).

Abstract: A device (10) for performing an allergy test comprising a container unit (11) having a first surface (12) and a second surface (13). The container unit (11) comprising a plurality of cavities (22) each arranged for receiving an allergen container (14) comprising a supporting material (18) and a pricking tool, which is secured at a location of the supporting material (18). The supporting material (18) is arranged, when a pressure force is applied on the second surface (13), for being compressed thereby causing the pricking tool (19) for being displaced from a first position (25), wherein at said first position the at least one pricking tip (24) is at a first distance from the first surface (12), to a second position (26), wherein at said second position (26) the at least one pricking tip (24) is at a second distance from the first surface (12).

Abstract: A nasal solution and method for treating nasal and sinus inflammation. The nasal solution includes vitamin C, an extract of scutellaria radix, an extract of eleutherococcus radix, an extract of chamomile, and a pharmaceutically acceptable carrier which is suitable for administering the vitamin C, the scutellaria radix extract; the eleutherococcus radix extract; and the chamomile to the nose of a patient. The method includes administering the nasal solution which suppresses early phase and late phase mediators of allergic mucosal disease in order to maintain long-term inhibition of nasal and sinus inflammation.

Abstract: A nasal solution and method for treating nasal and sinus inflammation. The nasal solution includes vitamin C, an extract of scutellaria radix, an extract of eleutherococcus radix, an extract of chamomile, and a pharmaceutically acceptable carrier which is suitable for administering the vitamin C, the scutellaria radix extract; the eleutherococcus radix extract; and the chamomile to the nose of a patient. The method includes administering the nasal solution which suppresses early phase and late phase mediators of allergic mucosal disease in order to maintain long-term inhibition of nasal and sinus inflammation.

Abstract: The present invention relates to methods of treating nasal polyposis, in a human, comprising the step of administering to said human in need thereof an effective amount of a composition comprising at least one anti-11-5 antibody wherein said antibody comprises a heavy chain and a light chain.

Abstract: The invention concerns a device (1) for performing an allergy test. Said device (1) comprises a container assembly (2) including several containers (3) designed to receive the allergens, and a mark transferable onto the skin which is used to associate specific allergens to specific allergy sites on the skin of a living being undergoing an allergy test. The invention aims at improving said device (1) so that the allergy test sites on the skin can be constantly marked very legibly, and so that the corresponding marks can be readily eliminated from the skin immediately after the allergy test. Therefor, the transferable mark is formed by at least one marking unit (6) which is removably fixed on said device (1), and whereof the side, facing towards the skin during the allergy test, is at least partly coated with an adhesive substance, such that the device (1) can be spaced apart while the marking unit (6) remains on the skin.

Abstract: The present invention relates to a stent, adapted for deployment in a nasal sinus, comprising a matrix metalloproteinase-inhibiting substance and capable of locally releasing in a controlled manner a therapeutically effective amount of said matrix metalloproteinase-inhibiting substance. The invention further relates to a method for treatment of a diseased or damaged sinus mucosal tissue in a patient, said method comprising introducing into the sinus of said patient a stent comprising a matrix metalloproteinase-inhibiting substance.